CVS Caremark Reinstates Zepbound, Adds Foundayo Coverage, Boosting Lilly's Key Drug Sales
LLY sits 81% above its 52-week low of $623.78.
Summary
CVS Caremark is reinstating Eli Lilly's blockbuster weight-loss drug Zepbound to its preferred drug list, effective October, and will also cover the newly approved weight-loss pill Foundayo starting June 1. This move reverses CVS's previous decision to remove Zepbound, which had led to market share losses to competitors. The expanded insurance coverage significantly boosts market access and sales potential for two of Lilly's key growth drivers, contributing to the company's market capitalization returning above $1 trillion. This follows recent FDA approval for Foundayo and strong Q1 2026 financial results driven by Zepbound.
At the time of this announcement, LLY was trading at $1,130.04 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,149.10. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.